Michele Caruso

TL;DR: There is no difference in ORR, TTP, and OS for patients treated with the FOLFIRI or FOLFOX4 regimen, and both therapies seemed effective as first-line treatment in these patients.

TL;DR: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis, as evaluated in a single-arm, single-stage, open-label, multicenter, phase II trial.

TL;DR: The data reject the 'worst drug rule' hypothesis of sequential treatments in NSCCL at least with the combination used in this study, and indicate that the combination of vinorelbine and cisplatin and that of gemcitabine and cascplatin are equivalent in terms of median TTP and OS, although the vinorlbine-cisplatin regimen is associated with a higher ORR.

TL;DR: Male breast cancer shows different biological patterns compared with FBC, with higher positive hormone-receptor status and lower HER-2 overexpression, and grade 3 and Ki-67 >20% were associated with shorter overall survival and shorter OS.

TL;DR: A multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer, finding that musculoskeletal side-effects were more frequent with the upfront schedule than with the switch schedule.